Activation Markers on T Cells Infiltrating Melanoma Metastases After Therapy with Dinitrophenyl-conjugated Vaccine

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 1994 Sep 1

PMID 7923243

Citations 10

Authors

D Berd

H C MAGUIRE Jr

M J Mastrangelo

G Murphy

Affiliations

Soon will be listed here.

Abstract

Treatment of metastatic melanoma patients with an autologous vaccine modified by the hapten, dinitrophenyl (DNP), produces a striking immunological effect: the induction of clinically evident inflammatory responses in metastatic tumors. Histological examination shows these tumors to be infiltrated with T lymphocytes. We studied the expression of activation markers on those cells and compared them with matched peripheral blood lymphocytes (PBL) and with lymphocytes extracted from metastases before treatment with DNP-conjugated vaccine. The median fraction of cells that were T cells in post-vaccine tumors was 41%, as compared with 9% in pre-treatment tumors, and those T cells were predominantly CD8+ (mean CD8/CD4 ratio = 5.0). A high proportion of both pre- and post-treatment infiltrating T cells expressed HLA-DR (mean +/- SE = 48% +/- 4%), CD69 (56% +/- 7%), and ganglioside GD3 (68% +/- 5%). This distinguished them from matched PBL in which expression of those markers was significantly lower (HLA-DR = 10% +/- 2%; CD69 = 2% +/- 0.4%; GD3 = 49% +/- 4%). These changes were not accompanied by increased cell-surface expression of interleukin-2 (IL-2) receptors, either CD25 or p75, which were expressed by 1%-2% and 12% of tumor-infiltrating lymphocytes (TIL), respectively. The pattern of activation marker expression that we identified appears to be characteristic of tissue T cells with the memory phenotype. The low expression of IL-2 receptors could indicate functional impairment of TIL in situ, perhaps because of inhibitory molecules produced by melanoma cells.

Citing Articles

Portrait of an autologous cancer vaccine: Then and now.

Berd D Hum Vaccin Immunother. 2023; 19(1):2172925.

PMID: 36755486 PMC: 10012894. DOI: 10.1080/21645515.2023.2172925.

Antibody-dependent cellular phagocytosis of tropomyosin receptor kinase C (TrkC) expressing cancer cells for targeted immunotherapy.

Lai P, Usama S, Kiew L, Lee H, Chung L, Burgess K Cancer Immunol Immunother. 2022; 71(9):2099-2108.

PMID: 35032175 PMC: 10365225. DOI: 10.1007/s00262-022-03147-y.

Pancreatic cancer cell/fibroblast co-culture induces M2 like macrophages that influence therapeutic response in a 3D model.

Kuen J, Darowski D, Kluge T, Majety M PLoS One. 2017; 12(7):e0182039.

PMID: 28750018 PMC: 5531481. DOI: 10.1371/journal.pone.0182039.

Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.

Moran A, Polesso F, Weinberg A J Immunol. 2016; 197(6):2509-21.

PMID: 27503208 PMC: 5010950. DOI: 10.4049/jimmunol.1502659.

Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.

Melichar B, Nash M, Lenzi R, Platsoucas C, Freedman R Clin Exp Immunol. 1999; 119(1):19-27.

PMID: 10606960 PMC: 1905534. DOI: 10.1046/j.1365-2249.2000.01105.x.

References

Cantrell D, Smith K . Transient expression of interleukin 2 receptors. Consequences for T cell growth. J Exp Med. 1983; 158(6):1895-911. PMC: 2187178. DOI: 10.1084/jem.158.6.1895. View

Miller S, Claman H . The induction of hapten-specific T cell tolerance by using hapten-modified lymphoid cells. I. Characteristics of tolerance induction. J Immunol. 1976; 117(5 Pt 1):1519-26. View

Lewis R, Buchsbaum M, Whitaker D, Murphy G . Intercellular adhesion molecule expression in the evolving human cutaneous delayed hypersensitivity reaction. J Invest Dermatol. 1989; 93(5):672-7. DOI: 10.1111/1523-1747.ep12319838. View

Evans R, Faldetta T, Humphreys R, Pratt D, Yunis E, Schlossman S . Peripheral human T cells sensitized in mixed leukocyte culture synthesize and express Ia-like antigens. J Exp Med. 1978; 148(5):1440-5. PMC: 2185039. DOI: 10.1084/jem.148.5.1440. View

CARDI G, Mastrangelo M, Berd D . Depletion of T-cells with the CD4+CD45R+ phenotype in lymphocytes that infiltrate subcutaneous metastases of human melanoma. Cancer Res. 1989; 49(23):6562-5. View

Rosenberg S, Packard B, Aebersold P, Solomon D, Topalian S, TOY S . Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319(25):1676-80. DOI: 10.1056/NEJM198812223192527. View

Picker L, Treer J, Collins P, Bergstresser P, Terstappen L . Control of lymphocyte recirculation in man. II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin-homing T cells. J Immunol. 1993; 150(3):1122-36. View

Alexander J, Kudoh S, Melsop K, Hamilton T, Edinger M, Tubbs R . T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res. 1993; 53(6):1380-7. View

Berd D, MAGUIRE Jr H, Mastrangelo M . Treatment of human melanoma with a hapten-modified autologous vaccine. Ann N Y Acad Sci. 1993; 690:147-52. DOI: 10.1111/j.1749-6632.1993.tb44004.x. View

10.

Anichini A, Fossati G, Parmiani G . Clonal analysis of the cytolytic T-cell response to human tumors. Immunol Today. 2014; 8(12):385-9. DOI: 10.1016/0167-5699(87)90215-5. View

11.

Finke J, Zea A, Stanley J, Longo D, Mizoguchi H, Tubbs R . Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993; 53(23):5613-6. View

12.

Murphy G, Radu A, Kaminer M, Berd D . Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy. J Invest Dermatol. 1993; 100(3):335S-341S. DOI: 10.1111/1523-1747.ep12470236. View

13.

Cohen P, Lotze M, Roberts J, Rosenberg S, Jaffe E . The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol. 1987; 129(2):208-16. PMC: 1899728. View

14.

Welte K, Miller G, Chapman P, Yuasa H, Natoli E, Kunicka J . Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J Immunol. 1987; 139(6):1763-71. View

15.

Berd D, MAGUIRE Jr H, Mastrangelo M . Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 1986; 46(5):2572-7. View

16.

Cotner T, Williams J, CHRISTENSON L, Shapiro H, Strom T, Strominger J . Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content. J Exp Med. 1983; 157(2):461-72. PMC: 2186946. DOI: 10.1084/jem.157.2.461. View

17.

Hersey P, Jamal O . Expression of the gangliosides GD3 and GD2 on lymphocytes in tissue sections of melanoma. Pathology. 1989; 21(1):51-8. DOI: 10.3109/00313028909059531. View

18.

Berd D, Murphy G, MAGUIRE Jr H, Mastrangelo M . Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res. 1991; 51(10):2731-4. View

19.

Hersey P, Schibeci S, Townsend P, Burns C, Cheresh D . Potentiation of lymphocyte responses by monoclonal antibodies to the ganglioside GD3. Cancer Res. 1986; 46(12 Pt 1):6083-90. View

20.

Picker L, Treer J, Collins P, Buck D, Terstappen L . Control of lymphocyte recirculation in man. I. Differential regulation of the peripheral lymph node homing receptor L-selectin on T cells during the virgin to memory cell transition. J Immunol. 1993; 150(3):1105-21. View